Literature DB >> 22849289

Robot-assisted reconstructive surgery for ureteral malignancy: analysis of efficacy and oncologic outcomes.

Paul D McClain1, Patrick W Mufarrij, Ashok K Hemal.   

Abstract

BACKGROUND AND
PURPOSE: There have been previous reports of the use of robotic technology for the surgical treatment of ureteral neoplasms such as transitional-cell carcinoma. These have lacked long-term follow-up, been isolated cases, or focused on only the distal ureter. This investigation examines a series of mid and distal ureteral neoplasms managed with surgeon controlled robotic techniques at a tertiary care medical center. We present perioperative data and long-term follow-up, with emphasis on oncologic outcomes. PATIENTS AND METHODS: This series includes six consecutive patients who have undergone robot-assisted surgical extirpation of mid and distal ureteral malignancies since 2008. Four patients underwent robot-assisted distal ureterectomy with ureteroneocystostomy, and two underwent midureter segmental excision with ureteroureterostomy. Patient demographics, intraoperative data, final pathology results, and oncologic follow-up were reviewed retrospectively.
RESULTS: Total mean operative time was 268.5 minutes, including the cystoscopy and change of position component of the procedure; mean estimated blood loss was 72.5 mL, and the mean length of stay was 1.8 days. All four patients who underwent distal ureterectomy also had excisions of the ipsilateral bladder cuff-three needed a psoas hitch to facilitate the ureteroneocystostomy. Final pathology results revealed four cases of transitional-cell carcinoma, one case of ureteral carcinoma in situ, and one case of non-Hodgkin diffuse-type B-cell lymphoma. The only complication was a small hydrocele in one patient. All patients underwent standard surveillance protocol, with a recurrence in the bladder developing in one patient. Ureteral obstruction did not develop in any patient postoperatively. Mean length of follow-up was 33 months.
CONCLUSIONS: Robot-assisted surgery is well suited for the complex reconstruction of the mid and distal ureter after excision of low-grade malignant lesions. This series demonstrates that this surgical approach offers excellent intermediate-term oncologic outcomes with preservation of ipsilateral renal function. We believe that robotic surgery may be considered as a first-line option for the minimally invasive excision and reconstruction of low-grade, localized ureteral malignancy in selected patients at centers with experienced teams.

Entities:  

Mesh:

Year:  2012        PMID: 22849289     DOI: 10.1089/end.2012.0219

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  7 in total

1.  Urothelial-based reconstructive surgery for upper- and mid-ureteral defects: Long-term results.

Authors:  Barak Rosenzweig; Yoram Mor; Tomer Erlich; Menachem Laufer; Harry Winkler; Issac Kaver; Jacob Ramon; Zohar A Dotan
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

Review 2.  Robotic assisted reconstruction for complications following urologic oncologic procedures.

Authors:  Daisy Obiora; Hailiu Yang; Ronak A Gor
Journal:  Transl Androl Urol       Date:  2021-05

3.  Robotic distal ureterectomy with psoas hitch and ureteroneocystostomy: Surgical technique and outcomes.

Authors:  Joseph Pugh; Amy Farkas; Li-Ming Su
Journal:  Asian J Urol       Date:  2015-04-16

Review 4.  Robotic versus laparoscopic colorectal surgery.

Authors:  Becky B Trinh; Nicole R Jackson; Adam T Hauch; Tian Hu; Emad Kandil
Journal:  JSLS       Date:  2014 Oct-Dec       Impact factor: 2.172

5.  Robot-assisted versus standard laparoscopic colorectal surgery.

Authors:  Becky B Trinh; Adam T Hauch; Joseph F Buell; Emad Kandil
Journal:  JSLS       Date:  2014 Oct-Dec       Impact factor: 2.172

Review 6.  Expanding the indications of robotic surgery in urology: A systematic review of the literature.

Authors:  Raj P Pal; Anthony J Koupparis
Journal:  Arab J Urol       Date:  2018-08-07

Review 7.  Nephron-sparing approaches in the management of upper tract urothelial carcinoma: indications and clinical outcomes.

Authors:  Young Hwii Ko
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.